Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (5) 5
androgens (3) 3
castration (3) 3
metastases (3) 3
metastasis (3) 3
patients (3) 3
prostate cancer (3) 3
survival (3) 3
antigens (2) 2
cancer therapies (2) 2
care and treatment (2) 2
clinical-trials (2) 2
functional assessment (2) 2
men (2) 2
oncology (2) 2
pain (2) 2
prostate (2) 2
prostate-specific antigen (2) 2
quality of life (2) 2
research & development--r&d (2) 2
80 and over (1) 1
abridged index medicus (1) 1
adenocarcinoma (1) 1
adenocarcinoma - drug therapy (1) 1
adenocarcinoma - secondary (1) 1
adenocarcinoma; aged; aged, 80 and over; androgen antagonists; disease progression; disease-free survival; double-blind method; exanthema; humans; male; middle aged; neoplasm metastasis; proportional hazards models; prostate-specific antigen; prostatic neoplasms, castration-resistant; thiohydantoins; medicine (1) 1
adverse effects (1) 1
aged (1) 1
aged, 80 and over (1) 1
analysis (1) 1
androgen antagonists (1) 1
androgen antagonists - adverse effects (1) 1
androgen antagonists - therapeutic use (1) 1
androgen-deprivation therapy (1) 1
antigen (1) 1
arn-509 (1) 1
basic medicine (1) 1
bone metastases (1) 1
cancer and oncology (1) 1
cancer och onkologi (1) 1
castration-resistant (1) 1
chemically induced (1) 1
chemotherapy (1) 1
clinical medicine (1) 1
clinical trials (1) 1
design (1) 1
disease progression (1) 1
disease-free survival (1) 1
double-blind method (1) 1
drug therapy (1) 1
enzalutamide (1) 1
event-related potentials (1) 1
exanthema (1) 1
exanthema - chemically induced (1) 1
family medical history (1) 1
farmakologi och toxikologi (1) 1
fatigue (1) 1
fda approval (1) 1
funding (1) 1
hospitals (1) 1
humans (1) 1
hypothyroidism (1) 1
impact (1) 1
information sharing (1) 1
interference (1) 1
klinisk medicin (1) 1
laboratories (1) 1
ligands (1) 1
lymphatic system (1) 1
male (1) 1
medical and health sciences (1) 1
medical imaging (1) 1
medical research (1) 1
medicin och hälsovetenskap (1) 1
medicine, general & internal (1) 1
medicinska och farmaceutiska grundvetenskaper (1) 1
metastasis-free survival (1) 1
middle aged (1) 1
motivation (1) 1
neoplasm metastasis (1) 1
neoplasm metastasis - prevention & control (1) 1
pathology (1) 1
pharmacology and toxicology (1) 1
preservation (1) 1
prevention & control (1) 1
proportional hazards models (1) 1
prostatic neoplasms (1) 1
prostatic neoplasms, castration-resistant - drug therapy (1) 1
prostatic neoplasms, castration-resistant - pathology (1) 1
recommendations (1) 1
reported outcomes (1) 1
risk groups (1) 1
secondary (1) 1
skeletal-related events (1) 1
studies (1) 1
tablets (1) 1
therapeutic use (1) 1
therapy (1) 1
thiohydantoins (1) 1
thiohydantoins - adverse effects (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
by Smith, Matthew R and Saad, Fred and Chowdhury, Simon and Oudard, Stéphane and Hadaschik, Boris A and Graff, Julie N and Olmos, David and Mainwaring, Paul N and Lee, Ji Youl and Uemura, Hiroji and Lopez-Gitlitz, Angela and Trudel, Géralyn C and Espina, Byron M and Shu, Youyi and Park, Youn C and Rackoff, Wayne R and Yu, Margaret K and Small, Eric J and SPARTAN Investigators and Sahlgrenska akademin and Institute of Clinical Sciences and Institutionen för kliniska vetenskaper and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
The New England Journal of Medicine, ISSN 0028-4793, 04/2018, Volume 378, Issue 15, pp. 1408 - 1418
Among men with nonmetastatic prostate cancer who had a rapid PSA doubling time and were receiving androgen-deprivation therapy, the median metastasis-free... 
MEDICINE, GENERAL & INTERNAL | THERAPY | LIGANDS | BONE METASTASES | MEN | ARN-509 | ANTIGEN | Prostate-Specific Antigen | Double-Blind Method | Humans | Middle Aged | Proportional Hazards Models | Male | Prostatic Neoplasms, Castration-Resistant - drug therapy | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Disease Progression | Prostatic Neoplasms, Castration-Resistant - pathology | Disease-Free Survival | Thiohydantoins - adverse effects | Exanthema - chemically induced | Neoplasm Metastasis - prevention & control | Thiohydantoins - therapeutic use | Aged, 80 and over | Androgen Antagonists - therapeutic use | Aged | Androgen Antagonists - adverse effects | Prostate cancer | Care and treatment | Metastasis | Medical research | Antigens | Lymphatic system | Medical imaging | Prostate-specific antigen | Research & development--R&D | Family medical history | Hypothyroidism | Survival | Patients | Metastases | Androgens | Hospitals | Castration | Prostate | Adenocarcinoma | pathology | Androgen Antagonists | Exanthema | 80 and over | Prostatic Neoplasms | Neoplasm Metastasis | Thiohydantoins | Urologi och njurmedicin | drug therapy | chemically induced | Castration-Resistant | prevention & control | secondary | adverse effects | Urology and Nephrology | therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial
by Saad, Fred and Cella, David and Basch, Ethan and Hadaschik, Boris A and Mainwaring, Paul N and Oudard, Stéphane and Graff, Julie N and McQuarrie, Kelly and Li, Susan and Hudgens, Stacie and Lawson, Joe and Lopez-Gitlitz, Angela and Yu, Margaret K and Smith, Matthew R and Small, Eric J
The Lancet Oncology, ISSN 1470-2045, 10/2018, Volume 19, Issue 10, pp. 1404 - 1416
In the SPARTAN trial, addition of apalutamide to androgen deprivation therapy, as compared with placebo plus androgen deprivation therapy, significantly... 
ANDROGEN-DEPRIVATION THERAPY | IMPACT | REPORTED OUTCOMES | ONCOLOGY | FUNCTIONAL ASSESSMENT | CLINICAL-TRIALS | MEN | SKELETAL-RELATED EVENTS | METASTASIS-FREE SURVIVAL | CHEMOTHERAPY | ENZALUTAMIDE | Clinical trials | Care and treatment | Metastasis | Prostate cancer | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Understanding symptomatic experience, impact, and emotional response in recently diagnosed metastatic castration-resistant prostate cancer: a qualitative study
by Burbridge, Claire and Randall, Jason A and Lawson, Joe and Symonds, Tara and Dearden, Lindsay and Lopez-Gitlitz, Angela and Espina, Byron and McQuarrie, Kelly
Supportive Care in Cancer, ISSN 0941-4355, 10/2019
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study
by Agarwal, Neeraj and McQuarrie, Kelly and Bjartell, Anders and Chowdhury, Simon and Pereira de Santana Gomes, Andrea J and Chung, Byung Ha and Özgüroğlu, Mustafa and Juárez Soto, Álvaro and Merseburger, Axel S and Uemura, Hirotsugu and Ye, Dingwei and Given, Robert and Cella, David and Basch, Ethan and Miladinovic, Branko and Dearden, Lindsay and Deprince, Kris and Naini, Vahid and Lopez-Gitlitz, Angela and Chi, Kim N and TITAN Investigators and Lund University and Urological cancer, Malmö and Urologisk cancerforskning, Malmö and EpiHealth: Epidemiology for Health and eSSENCE: The e-Science Collaboration and BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation and Lunds universitet
The Lancet Oncology, ISSN 1470-2045, 11/2019, Volume 20, Issue 11, pp. 1518 - 1530
In the phase 3 TITAN study, the addition of apalutamide to androgen deprivation therapy (ADT) significantly improved the primary endpoints of overall survival... 
DESIGN | ONCOLOGY | FUNCTIONAL ASSESSMENT | RECOMMENDATIONS | CLINICAL-TRIALS | Clinical Medicine | Basic Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Medicinska och farmaceutiska grundvetenskaper | Farmakologi och toxikologi | Klinisk medicin | Cancer and Oncology | Pharmacology and Toxicology | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Relationship of time to metastasis (TTM) and site of metastases in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Results from the phase 3 SPARTAN trial
by Smith, Matthew Raymond and Saad, Fred and Rathkopf, Dana E and Hadaschik, Boris A and Chowdhury, Simon and Yu, Margaret K and Lopez-Gitlitz, Angela and Rooney, Oliver Brendan and Darif, Mohamed and Small, Eric Jay
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. 5033 - 5033
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text PD10-11 PROSTATE-SPECIFIC ANTIGEN (PSA) OUTCOMES IN PATIENTS (PTS) WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) TREATED WITH APALUTAMIDE (APA): RESULTS FROM PHASE 3 SPARTAN STUDY
by Small, Eric J and Lee, Ji Youl and Lopez-Gitlitz, Angela and Saad, Fred and Rooney, Brendan and Hadaschik, Boris A and Uemura, Hiroji and Shu, Youyi and Yu, Margaret and Smith, Matthew R
The Journal of Urology, ISSN 0022-5347, 04/2018, Volume 199, Issue 4, pp. e232 - e232
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text MP52-20 PATIENT REPORTED OUTCOMES (PROS) IN SPARTAN, A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY OF APALUTAMIDE (APA) PLUS ANDROGEN DEPRIVATION THERAPY (ADT) VS PLACEBO PLUS ADT IN MEN WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC)
by Small, Eric J and Saad, Fred and Hadaschik, Boris A and Graff, Julie N and Mainwaring, Paul N and McQuarrie, Kelly and Li, Susan and Lawson, Joe and Lopez-Gitlitz, Angela and Smith, Matthew R
The Journal of Urology, ISSN 0022-5347, 04/2018, Volume 199, Issue 4, pp. e703 - e704
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Age-related efficacy and safety of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in subgroups of patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Post hoc analysis of SPARTAN
by Graff, Julie Nicole and Smith, Matthew Raymond and Saad, Fred and Hadaschik, Boris A and Uemura, Hiroji and Lee, Ji Youl and Mainwaring, Paul N and Olmos, David and Oudard, Stephane and Londhe, Anil and Bhaumik, Amitabha and Rooney, Oliver Brendan and Lopez-Gitlitz, Angela and Small, Eric Jay
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. 5024 - 5024
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Efficacy of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) and baseline (BL) comorbidities (CM)
by Small, Eric Jay and Saad, Fred and Chowdhury, Simon and Oudard, Stephane and Hadaschik, Boris A and Graff, Julie Nicole and Olmos, David and Mainwaring, Paul N and Lee, Ji Youl and Uemura, Hiroji and Lopez-Gitlitz, Angela and Londhe, Anil and Bhaumik, Amitabha and Cheng, Shinta and Rooney, Oliver Brendan and Smith, Matthew Raymond
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. 5023 - 5023
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Abstract 2605: Androgen receptor (AR) anomalies and efficacy of apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 SPARTAN study
by Smith, Matthew R and Thomas, Shibu and Chowdhury, Simon and Olmos, David and Li, Jinhui and Mainwaring, Paul N and Oudard, Stéphane and Feng, Felix Y and Gormley, Michael and Ricci, Deborah S and Rooney, Brendan and Lopez-Gitlitz, Angela and Yu, Margaret K and Small, Eric J
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. 2605 - 2605
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Predicting disease progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): An analysis from the phase 3 SPARTAN trial
by Small, Eric Jay and Saad, Fred and Rathkopf, Dana E and Hadaschik, Boris A and Chowdhury, Simon and Yu, Margaret K and Lopez-Gitlitz, Angela and Rooney, Oliver Brendan and Shu, Youyi and Darif, Mohamed and Smith, Matthew Raymond
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. 5034 - 5034
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Prostate-Specific Membrane Antigen Ligand Positron-Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer
by Fendler, Wolfgang P and Weber, Manuel and Iravani, Amir and Hofman, Michael S and Calais, Jérémie and Czernin, Johannes and Ilhan, Harun and Saad, Fred and Small, Eric J and Smith, Matthew R and Perez, Paola M and Hope, Thomas A and Rauscher, Isabel and Londhe, Anil and Lopez-Gitlitz, Angela and Cheng, Shinta and Maurer, Tobias and Herrmann, Ken and Eiber, Matthias and Hadaschik, Boris
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 09/2019
Systemic androgen-signaling inhibition added to ongoing androgen-deprivation therapy (ADT) improved clinical outcomes in patients with nonmetastatic... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Predictors of falls and fractures in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide (APA) plus ongoing androgen deprivation therapy (ADT)
by Pollock, YaoYao Guan and Smith, Matthew Raymond and Saad, Fred and Chowdhury, Simon and Oudard, Stephane and Hadaschik, Boris A and Olmos, David and Mainwaring, Paul N and Lee, Ji Youl and Uemura, Hiroji and Bhaumik, Amitabha and Londhe, Anil and Rooney, Oliver Brendan and Lopez-Gitlitz, Angela and Mundle, Suneel and Cheng, Shinta and Small, Eric Jay
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. 5025 - 5025
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN trial
by Feng, Felix Y and Thomas, Shibu and Gormley, Michael and Lopez-Gitlitz, Angela and Yu, Margaret K and Cheng, Shinta and Ricci, Deborah S and Rooney, Oliver Brendan and Mainwaring, Paul N and Olmos, David and Saad, Fred and Chowdhury, Simon and Hadaschik, Boris A and Fishbane, Nicholas and Davicioni, Elai and Liu, Yang and Small, Eric Jay and Smith, Matthew Raymond
Journal of Clinical Oncology, ISSN 0732-183X, 03/2019, Volume 37, Issue 7_suppl, pp. 42 - 42
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC)
by Small, Eric Jay and Saad, Fred and Chowdhury, Simon and Oudard, Stephane and Hadaschik, Boris A and Graff, Julie Nicole and Olmos, David and Mainwaring, Paul N and Lee, Ji Youl and Uemura, Hiroji and Lopez-Gitlitz, Angela and Espina, Byron M and Shu, Youyi and Rackoff, Wayne R and Rooney, Oliver Brendan and Londhe, Anil and Cheng, Shinta and Smith, Matthew Raymond
Journal of Clinical Oncology, ISSN 0732-183X, 03/2019, Volume 37, Issue 7_suppl, pp. 144 - 144
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC)
by Small, Eric Jay and Saad, Fred and Chowdhury, Simon and Hadaschik, Boris A and Graff, Julie Nicole and Olmos, David and Mainwaring, Paul N and Uemura, Hiroji and Lopez-Gitlitz, Angela and Trudel, Geralyn Carol and Espina, Byron M and Shu, Youyi and Park, Youn C and Rackoff, Wayne R and Yu, Margaret K and Smith, Matthew Raymond and On Behalf of the SPARTAN investigators
Journal of Clinical Oncology, ISSN 0732-183X, 02/2018, Volume 36, Issue 6_suppl, pp. 161 - 161
161 Background: Pts with nmCRPC are at risk for developing metastatic disease and cancer-specific mortality. There are no approved treatments for nmCRPC. APA... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.